Ascendis Pharma company profile

ASND · NASDAQ · USD

Compare Ascendis Pharma
$271.19Change from previous close: −0.20%Absolute change: −$0.54

Close · November 17, 2026

Company profile

Ascendis Pharma has 1,189 employees and is headquartered in Hellerup, Denmark.

Founded in 2006, Ascendis Pharma A/S is based in Hellerup, Denmark, and develops therapies built on its TransCon technology for rare conditions with unmet medical needs in Europe, the United States and other markets. Its marketed products include SKYTROFA, prescribed to children with growth hormone shortfall, and YORVIPATH, a daily subcutaneous injection for adults with chronic hypoparathyroidism. The company also has three endocrinology rare disease candidates in clinical development and advances oncology candidates.

In the fiscal year ended December 31, 2025, revenue reached 720.1 million euros, up 98.0% on the previous year, and the company recorded a net loss of 228.0 million euros. The United States accounted for 72.9% of revenue, Europe for 16.1%, the rest of the world for 7.0% and Denmark for 1.7%. The company employs 1,189 people.

Company facts

Industry
Biotechnology
Headquarters
Tuborg Boulevard 12, 2900, Hellerup
Employees
1,189
Chief executive
Jan Mikkelsen
Founded
2006
Fiscal year
January - December
Listing
ASND · NASDAQ
Currency
USD
ISIN
DK0060615755

Ascendis Pharma and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
Ascendis PharmaASNDUnited States$18.06B1,18930.9%18.1
ExelixisEXELUnited States$16.37B1,07740.2%20.1
Jazz PharmaceuticalsJAZZUnited States$15.5B2,89027.4%71.5
BioNTechBNTXUnited States$21.22B7,807-55.4%—
BridgeBio PharmaBBIOUnited States$15.25B1,081-37.3%—
Alnylam PharmaceuticalsALNYUnited States$22.11B2,50019.5%8.34

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare Ascendis Pharma with its competitors